Objective  To compare the efficacy and safety of linezolid and vancomycin in the treatment of hospitalized patients with Enterococcus bloodstream infection, to provide medication choices for clinical practice.

Methods  The clinical data of 99 inpatients with Enterococcus bloodstream infection in Yantai Yuhuangding Hospital from June 2019 to June 2023 were retrospectively collected, and the patients were divided into linezolid group and vancomycin group according to the drug used. confounding factors were controlled by propensity score matching method. The clinical efficacy, inflammatory factor levels, and adverse reactions of the two groups were compared.

Results  After using propensity score matching, 25 patients were assigned to both linezolid group and vancomycin group. There was no significant difference in the effective rate, 30- day mortality, incidence of adverse reactions and inflammatory factor levels between the two groups (P>0.05).

Conclusion  In the treatment of patients with Enterococcus bloodstream infection, the efficacy and safety of linezolid and vancomycin are the same. Linezolid can be a prioritized medicine when vancomycin causes nephrotoxicity and concentration does not meet the standard or exceeds the standard. Due to limitation of sample size and information collection, more high-quality studies are required to verify above conclusions.

1.全国细菌耐药监测网. 全国细菌耐药监测网2014-2019年血标本病原菌耐药性变迁[J]. 中国感染控制杂志, 2021, 20(2): 124-133. DOI: 10.12138/j.issn.1671- 9638.20216173.

2.Ong DS, Bonten MJ, Safdari K, et al. Epidemiology, management, and risk-adjusted mortality of ICU-acquired Enterococcal bacteremia[J]. Clin Infect Dis, 2015, 61(9): 1413-1420. DOI: 10.1093/cid/civ560.

3.万古霉素临床应用剂量专家组. 万古霉素临床应用中国专家共识(2011版)[J]. 中国新药与临床杂志, 2011, 30(8): 561-573. DOI: 10.3760/cma.j.issn.1000-6680. 2012.11.001.

4.Echeverria D, Sorli L, Prim N, et al. Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score matched comparative study[J]. Int J Antimicrob Agents, 2019, 54(5): 572-578. DOI: 10.1016/j.ijantimicag.2019.08.018.

5.原国家卫生部. 医院感染诊断标准(试行)摘登(2)(续前) [J]. 新医学, 2005, 36(12): 735. DOI: 10.3969/j.issn. 0253-9802.2005.12.036.

6.原国家卫生部, 国家中医药管理局, 总后卫生部. 抗菌药物临床应用指导原则[S]. 2004.

7.Bender JK, Cattoir V, Hegstad K, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in Enterococci in Europe: towards a common nomenclature[J]. Drug Resist Updat, 2018, 40: 25-39. DOI: 10.1016/j.drup.2018.10.002.

8.陈亮, 李真, 刘颖, 等. 肠球菌血流感染的临床特征和预后因素分析[J]. 中华医院感染学杂志, 2017, 27(9): 1944-1947. [Chen L, Li Z, Liu Y, et al. Clinical characteristics of bloodstream infections caused by Enterococci and prognostic factors[J]. Chinese Journal of Nosocomiology, 2017, 27(9): 1944-1947.] DOI: 10.11816/cn.ni.2017-163189.

9.张密, 陈延斌. 肠球菌属血流感染157例临床分析[J]. 江苏医药, 2016, 42(19): 2108-2111, 2068. [Zhang  M, Chen YB. A clinical analysis of 157 patients with Enterococcus bloodstream infection[J]. Jiangsu Medical Journal, 2016, 42(19): 2108-2111, 2068.] DOI: 10.19460/j.cnki.0253-3685.2016.19.011.

10.赵晖, 张千, 颜明明, 等. 基于上海市临床药事质量控制中心数据库的药物致血小板减少回顾性分析[J]. 药物流行病学杂志, 2022, 31(7): 454-462. [Zhao H, Zhang Q, Yan MM, et al. Drug-induced thrombocytopenia: a descriptive survey in adverse drug reaction spontaneous reporting database of Shanghai in China[J]. Chinese Journal of Pharmacoepidemiol, 2022, 31(7): 454-462.] DOI: 10.19960/j.cnki.issn1005-0698.2022.07.005.

11.Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association[J]. Circulation, 2015, 132(15): 1435-1486. DOI: 10.1161/CIR.0000000000000296.

12.匡欢, 钟册俊, 吕晓菊. 氨基糖苷类等抗菌药物的个体化治疗应用[J]. 中国抗生素杂志, 2019, 44(11): 1232-1237. [Kuang H, Zhong CJ, Lyu XJ. Personalized chemotherapy application of antimicrobials including aminoglycosides[J]. Chinese Journal of Antibiotics, 2019, 44(11): 1232-1237.] DOI: 10.13461/j.cnki.cja.006819.

13.Nuria FH, Benito A, Joan G, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis[J]. Clin Infect Dis, 2013, 56(9): 1261-1268. DOI: 10.1093/cid/cit052.

14.Maya B, Luther MK, Rice LB, et al. A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis[J]. Clin Infect Dis, 2018, 67(2): 303-309. DOI: 10.1093/cid/ciy064.

15.郭燕, 胡付品, 朱德妹, 等. 2022年CHINET三级医院细菌耐药监测[J]. 中国感染与化疗杂志, 2024, 24(3): 277-286. [Guo Y, Hu FP, Zhu DM, et al. Surveillance of bacterial resistance in tertiary hospitals across China: results of CHINET antimicrobial resistance surveillance program in 2022[J]. Chinese Journal of Infection and Chemotherapy, 2024, 24(3): 277-286.] DOI: 10.16718/j.1009-7708.2024.03.005.

16.王雪飞, 赵永生, 赵庆华, 等. 肝胆胰外科重症病房肠球菌耐药率变迁及中外数据库对比[J]. 中华医院感染学杂志, 2022, 32(22): 3429-3433. [Wang XF, Zhao YS, Zhao QH, et al. Changes of drug resistance rate of Enterococci in intensive care unit of hepatobiliary and pancreatic surgery department and comparative study of Chinese and foreign databases[J]. Chinese Journal of Nosocomiology, 2022, 32(22): 3429-3433.] DOI: 10.11816/cn.ni.2022-213683.

17.袁妍, 朱卫民. 耐万古霉素肠球菌患者的临床分布特点及耐药性分析[J]. 中国药房, 2022, 33(10): 1253-1257. [Yuan Y, Zhu WM. Analysis of clinical distribution and drug resistance of vancomycin-resistant Enterococci[J]. China Pharmacy, 2022, 33(10): 1253-1257.] DOI: 10.6039/j.issn.1001-0408.2022.10.16.

18.董海燕, 韩欣妍, 孟丹丹, 等. 脓毒症治疗中利奈唑胺与万古霉素对降钙素原和C反应蛋白影响的差异[J]. 中国感染与化疗杂志, 2020, 20(4): 406-412. [Dong  HY, Han XY, Meng DD, et al. Effects of linezolid versus vancomycin on procalcitonin and C-reactive protein in treatment of sepsis[J]. Chinese Journal of Infection and Chemotherapy, 2020, 20(4): 406-412.] DOI: 10.16718/j.1009-7708.2020.04.012.

19.卢萍, 周智恩, 姚娟. 万古霉素与利奈唑胺治疗脓毒症对C反应蛋白和降钙素原的影响[J]. 西部医学, 2022, 34(5): 757-760. [Lu P, Zhou ZE, Yao J. Difference study of linonazolamine and vancomycin on calcitonogen and C reactive protein in sepsis treatment[J]. Medical Journal of West China, 2022, 34(5): 757-760.] DOI: 10.3969/i.issn 1672-3511.2022.05.025.

20.Singh KV, Arias CA, Murray BE. Tedizolid as step-down therapy following daptomycin versus continuation of daptomycin against Enterococci and methicillin-and vancomycin-resistant Staphylococcus aureus in a rat endocarditis model[J]. Antimicrob Agents Chemother, 2020, 64(5): e02303-e02319. DOI: 10.1128/AAC.02303-19.

21.Kidd JM, Abdelraouf K, Asempa TE, et al. Pharmacodynamics of daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model[J]. Antimicrob Agents Chemother, 2018, 62(10): e00506-e00518. DOI: 10.1128/AAC.00506-18.

22.Echeverría ED, Sorli L, Prim N, et al. Daptomycin versus glycopeptides for the treatment of Enterococcus faecium bacteraemia: a cohort study[J]. Antibiotics (Basel), 2021, 10(6): 716. DOI: 10.3390/antibiotics10060716.